Antonino Neri

List of Publications by Citations

357 papers	14,860 citations	63 h-index	107 g-index
372 ext. papers	16,543 ext. citations	5.8 avg, IF	5.71 L-index

#	Paper	IF	Citations
357	Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. *Journal of Experimental Medicine*, **2001**, 194, 1625-38	16.6	731
356	p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 5413-7	11.5	691
355	International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. *Leukemia*, **2009**, 23, 2210-21	10.7	655
354	BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 11816-21	11.5	448
353	B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. *Cell*, **1991**, 67, 1075-87	56.2	388
352	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. *Blood*, **2008**, 111, 2765-75	2.2	217
351	Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. *Blood*, **2009**, 114, e20-6	2.2	213
350	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. *Nature Medicine*, **2014**, 20, 599-606	50.5	189
349	Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 2748-52	11.5	188
348	A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene. *Blood*, **1997**, 90, 4062-4070	2.2	187
347	Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. *Clinical Cancer Research*, **2012**, 18, 6260-70	12.9	185
346	Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. *Blood*, **2011**, 117, 553-62	2.2	182
345	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. *Blood*, **2015**, 126, 1921-4	2.2	167
344	Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. *Clinical Cancer Research*, **2013**, 19, 2096-106	12.9	165
343	Analysis of RAS oncogene mutations in human lymphoid malignancies. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 9268-72	11.5	160
342	IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. *Immunity*, **2001**, 14, 277-89	32.3	156
341	Ras oncogene mutation in multiple myeloma. *Journal of Experimental Medicine*, **1989**, 170, 1715-25	16.6	146

340	Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. *Stem Cells*, **2007**, 25, 1675-80	5.8	139
339	Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. *Leukemia*, **2018**, 32, 1948-1957	10.7	129
338	Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. *Journal of Clinical Oncology*, **2010**, 28, 1583-90	2.2	129
337	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. *Oncotarget*, **2012**, 3, 1246-58	3.3	127
336	Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. *Journal of Clinical Investigation*, **2006**, 116, 3171-82	15.9	126
335	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. *Blood*, **2018**, 131, 2413-2425	2.2	122
334	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. *Cell Death and Disease*, **2012**, 3, e436	9.8	122
333	A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. *Genes Chromosomes and Cancer*, **2009**, 48, 603-14	5	113
332	Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. *Journal of Clinical Oncology*, **2005**, 23, 7296-306	2.2	110
331	In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. *Oncotarget*, **2013**, 4, 242-55	3.3	109
330	Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. *Oncogene*, **2005**, 24, 2461-73	9.2	107
329	Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. *Journal of Clinical Oncology*, **2005**, 23, 5334-46	2.2	106
328	The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. *Blood*, **2007**, 110, 4464-75	2.2	104
327	The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. *Oncogene*, **2013**, 32, 2882-90	8.2	103
326	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. *Blood*, **2003**, 102, 1588-94	2.2	100
325	Anaplastic lymphoma kinase in human cancer. *Journal of Molecular Endocrinology*, **2011**, 47, R11-23	4.5	96
324	Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. *Leukemia*, **2012**, 26, 1391-401	10.7	95
323	Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. *Blood*, **2012**, 120, 5002-13	2.2	94

322	The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. *Leukemia*, **2007**, 21, 1892-900	10.7	94
321	An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. *BMC Medical Genomics*, **2008**, 1, 37	3.7	94
320	Low bone marrow oxygen tension and hypoxia-inducible factor-1 overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. *Leukemia*, **2010**, 24, 1967-70	10.7	91
319	Differential repetitive DNA methylation in multiple myeloma molecular subgroups. *Carcinogenesis*, **2009**, 30, 1330-5	4.6	91
318	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. *Clinical Cancer Research*, **2017**, 23, 2891-2904	12.9	90
317	Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. *Oncogene*, **2001**, 20, 3553-62	9.2	89
316	Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. *Leukemia*, **2015**, 29, 2173-83	10.7	86
315	miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. *Cell Cycle*, **2013**, 12, 3650-62	4.7	86
314	Hypoxia-inducible factor (HIF)-1 suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. *Leukemia*, **2013**, 27, 1697-706	10.7	82
313	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. *Blood*, **2012**, 120, 1274-81	2.2	80
312	Promises and challenges of MicroRNA-based treatment of multiple myeloma. *Current Cancer Drug Targets*, **2012**, 12, 838-46	2.8	80
311	Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. *Oncotarget*, **2014**, 5, 3039-54	3.3	80
310	Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. *Clinical Cancer Research*, **2009**, 15, 5369-78	12.9	79
309	Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. *Molecular and Cellular Biology*, **1995**, 15, 5180-7	4.8	79
308	Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. *Science*, **1997**, 278, 1969-70; author reply 1972-3	33.3	77
307	A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. *Journal of Cellular Physiology*, **2014**, 229, 2106-16	7	76
306	Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. *Clinical Cancer Research*, **2013**, 19, 3130-42	12.9	76
305	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. *British Journal of Haematology*, **2002**, 118, 817-20	4.5	75

304	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. *Molecular Cancer Therapeutics*, **2016**, 15, 1364-75	6.1	75
303	Structural and functional characterization of the promoter regions of the NFKB2 gene. *Nucleic Acids Research*, **1995**, 23, 2328-36	20.1	73
302	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. *Cancer Cell*, **2017**, 32, 88-100.e6	24.3	72
301	Autoimmune cytopenias in chronic lymphocytic leukemia. *American Journal of Hematology*, **2014**, 89, 1055-62	7.1	69
300	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. *Blood*, **1999**, 93, 1330-1337	2.2	68
299	Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). *American Journal of Pathology*, **2000**, 156, 1505-13	5.8	67
298	miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. *Oncotarget*, **2016**, 7, 12731-47	3.3	66
297	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. *Blood*, **2016**, 127, 221-32	2.2	65
296	Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. *Expert Opinion on Biological Therapy*, **2013**, 13 Suppl 1, S125-37	5.4	65
295	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. *Leukemia*, **2014**, 28, 222-5	10.7	63
294	Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. *Journal of Clinical Oncology*, **1998**, 16, 3069-77	2.2	63
293	Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. *Journal of Clinical Oncology*, **1999**, 17, 3150-9	2.2	63
292	The Kr□ppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. *Leukemia*, **2015**, 29, 503-7	10.7	62
291	Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. *Oncotarget*, **2016**, 7, 14814-30	3.3	62
290	Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. *British Journal of Haematology*, **2007**, 136, 565-73	4.5	61
289	Genotypic monoclonality in immunophenotypically polyclonal orbital lymphoid tumors. A model of tumor progression in the lymphoid system. The 1986 Wendell Hughes lecture. *Ophthalmology*, **1987**, 94, 980-94	7.3	61
288	Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. *Annals of Oncology*, **1998**, 9, 779-81	10.3	60
287	Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. *Blood*, **1994**, 84, 270-278	2.2	60

286	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. *Molecular Cancer Therapeutics*, **2016**, 15, 1364-1375	6.1	60
285	Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. *Genes Chromosomes and Cancer*, **2009**, 48, 521-31	5	57
284	Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. *Genes Chromosomes and Cancer*, **2007**, 46, 226-38	5	57
283	The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. *Blood Cancer Journal*, **2012**, 2, e96	7	55
282	Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). *British Journal of Haematology*, **2001**, 114, 362-4	4.5	55
281	Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. *Oncotarget*, **2015**, 6, 24205-17	3.3	55
280	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. *BMC Medical Genomics*, **2013**, 6, 27	3.7	54
279	Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. *Genes Chromosomes and Cancer*, **2008**, 47, 781-93	5	54
278	Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent In Situ Hybridization. *Blood*, **1999**, 94, 724-732	2.2	54
277	The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. *Clinical Cancer Research*, **2011**, 17, 7402-12	12.9	53
276	Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. *Leukemia*, **2002**, 16, 693-9	10.7	52
275	Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. *Leukemia*, **2018**, 32, 1044-1048	10.7	52
274	Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. *Experimental Hematology*, **2013**, 41, 387-97.e1	3.1	51
273	Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. *Clinical Cancer Research*, **2013**, 19, 5890-900	12.9	50
272	Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. *Epigenetics*, **2011**, 6, 188-94	5.7	50
271	Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. *Experimental Hematology*, **2010**, 38, 141-53	3.1	50
270	Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. *Leukemia*, **2014**, 28, 642-8	10.7	48
269	Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. *American Journal of Hematology*, **2013**, 88, 16-23	7.1	48

268	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ER metastatic breast cancer. *Nature Genetics*, **2017**, 49, 444-450	36.3	46
267	Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. *Clinical Cancer Research*, **2010**, 16, 5641-53	12.9	46
266	Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. *British Journal of Haematology*, **2009**, 146, 44-53	4.5	46
265	Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas **1997**, 79, 1114-1121		46
264	Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. *Oncotarget*, **2017**, 8, 106527-106537	3.3	46
263	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. *Leukemia*, **2020**, 34, 234-244	10.7	46
262	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. *Blood*, **2020**, 135, 1859-1869	2.2	45
261	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. *Oncotarget*, **2015**, 6, 17543-58	3.3	45
260	miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. *Blood Cancer Journal*, **2016**, 6, e380	7	44
259	High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. *British Journal of Haematology*, **2014**, 165, 629-39	4.5	44
258	Improved risk stratification in myeloma using a microRNA-based classifier. *British Journal of Haematology*, **2013**, 162, 348-59	4.5	44
257	Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. *Genes Chromosomes and Cancer*, **2005**, 42, 117-27	5	44
256	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. *Leukemia and Lymphoma*, **2010**, 51, 1424-43	1.9	43
255	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. *American Journal of Hematology*, **2016**, 91, 1090-1095	7.1	43
254	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. *Blood*, **2016**, 128, 2093-2095	2.2	42
253	microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. *Clinical Cancer Research*, **2014**, 20, 4141-53	12.9	41
252	CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. *Hematological Oncology*, **2009**, 27, 140-7	1.3	41
251	Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. *Oncogene*, **1997**, 14, 1805-10	9.2	41

250	Notch signaling drives multiple myeloma induced osteoclastogenesis. *Oncotarget*, **2014**, 5, 10393-406	3.3	41
249	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. *Blood*, **2018**, 132, 1050-1063	2.2	40
248	Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. *Leukemia*, **2013**, 27, 451-63	10.7	40
247	Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. *Clinical Cancer Research*, **2013**, 19, 3247-58	12.9	40
246	MicroRNAs in the pathobiology of multiple myeloma. *Current Cancer Drug Targets*, **2012**, 12, 823-37	2.8	40
245	Long non-coding RNAs in normal and malignant hematopoiesis. *Oncotarget*, **2016**, 7, 50666-50681	3.3	40
244	Notch signaling deregulation in multiple myeloma: A rational molecular target. *Oncotarget*, **2015**, 6, 26826-40	3.3	39
243	p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. *Laboratory Investigation*, **2002**, 82, 1327-34	5.9	38
242	Analysis of p53 and ras gene mutations in endometriosis. *Gynecologic and Obstetric Investigation*, **1994**, 38, 70-1	2.5	38
241	Transcriptional features of multiple myeloma patients with chromosome 1q gain. *Leukemia*, **2007**, 21, 1113-6	10.7	37
240	Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. *Oncotarget*, **2015**, 6, 19132-47	3.3	37
239	Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1 chemokine system. *International Journal of Biochemistry and Cell Biology*, **2015**, 66, 134-40	5.6	36
238	HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. *Leukemia*, **2011**, 25, 527-37	10.7	36
237	Identification of primary MAFB target genes in multiple myeloma. *Experimental Hematology*, **2009**, 37, 78-86	3.1	36
236	Identification of a tumor-associated mutant form of the NF-kappaB RelA gene with reduced DNA-binding and transactivating activities. *Oncogene*, **1997**, 14, 791-9	9.2	36
235	The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. *Journal of Pathology*, **2005**, 206, 337-45	9.4	36
234	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents. *Haematologica*, **2018**, 103, 80-90	6.6	35
233	Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. *PLoS ONE*, **2011**, 6, e24313	3.7	35

232	Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. *Oncotarget*, **2016**, 7, 2367-78	3.3	35
231	Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. *Haematologica*, **2010**, 95, 260-9	6.6	34
230	Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. *International Journal of Cancer*, **1998**, 79, 263-8	7.5	34
229	Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. *Leukemia*, **2009**, 23, 2027-33	10.7	33
228	ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. *Frontiers in Oncology*, **2012**, 2, 41	5.3	33
227	Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. *Haematologica*, **2009**, 94, 887-8	6.6	33
226	The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. *Leukemia and Lymphoma*, **2008**, 49, 1374-83	1.9	33
225	Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. *Haematologica*, **2007**, 92, 56-65	6.6	33
224	FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple Myeloma. *Blood*, **1998**, 92, 2987-2989	2.2	33
223	Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. *Journal of Clinical Oncology*, **1989**, 7, 338-43	2.2	33
222	Impact of host genes and strand selection on miRNA and miRNA* expression. *PLoS ONE*, **2011**, 6, e23854	3.7	33
221	lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. *Blood Cancer Journal*, **2016**, 6, e468	7	33
220	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. *Leukemia*, **2015**, 29, 1390-401	10.7	32
219	Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. *Genes Chromosomes and Cancer*, **2014**, 53, 612-21	5	32
218	The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. *Blood*, **2011**, 118, 6353-61	2.2	32
217	The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. *Leukemia and Lymphoma*, **1996**, 23, 43-8	1.9	32
216	Analysis of p53 gene mutations in acute myeloid leukemia. *American Journal of Hematology*, **1994**, 46, 304-9	7.1	32
215	Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. *Oncotarget*, **2016**, 7, 21353-61	3.3	32

214	Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. *Annals of Oncology*, **1999**, 10, 1349-54	10.3	31
213	The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. *Experimental Hematology*, **2012**, 40, 634-45.e10	3.1	30
212	Anaplastic large-cell lymphoma. *Seminars in Diagnostic Pathology*, **2011**, 28, 190-201	4.3	30
211	A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. *Oncotarget*, **2015**, 6, 26129-41	3.3	30
210	miR-22 suppresses DNA ligase III addiction in multiple myeloma. *Leukemia*, **2019**, 33, 487-498	10.7	29
209	B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. *American Journal of Hematology*, **2013**, 88, 32-6	7.1	29
208	Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. *Genes Chromosomes and Cancer*, **2003**, 37, 261-9	5	29
207	The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx. *Journal of Laryngology and Otology*, **1998**, 112, 455-9	1.8	29
206	Frequency of RAS and p53 mutations in acute promyelocytic leukemias. *Leukemia and Lymphoma*, **1993**, 11, 405-10	1.9	28
205	Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. *American Journal of Pathology*, **2001**, 158, 1599-603	5.8	27
204	Compendium of FAM46C gene mutations in plasma cell dyscrasias. *British Journal of Haematology*, **2016**, 174, 642-5	4.5	27
203	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. *Blood*, **2019**, 133, 156-167	2.2	27
202	expressing CD14CD16 monocytes expand in multiple myeloma patients leading to increased osteoclasts. *Haematologica*, **2017**, 102, 773-784	6.6	26
201	A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. *Scientific Reports*, **2018**, 8, 6557	4.9	25
200	Gene array profile identifies collagen type XV as a novel human osteoblast-secreted matrix protein. *Journal of Cellular Physiology*, **2009**, 220, 401-9	7	25
199	Identification of a novel gene, PSD, adjacent to NFKB2/lyt-10, which contains Sec7 and pleckstrin-homology domains. *Genomics*, **1997**, 46, 251-9	4.3	25
198	Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. *Oncotarget*, **2016**, 7, 56013-56029	3.3	25
197	Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow. *Annals of Hematology*, **1998**, 76, 81-3	3	24

196	Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. *International Journal of Cancer*, **2001**, 92, 666-70	7.5	24
195	Multiple genetic lesions in laryngeal squamous cell carcinomas. *Cancer*, **1995**, 75, 1292-301	6.4	24
194	Inactivation of CK1 in multiple myeloma empowers drug cytotoxicity by affecting AKT and catenin survival signaling pathways. *Oncotarget*, **2017**, 8, 14604-14619	3.3	24
193	Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. *Leukemia*, **2017**, 31, 1894-1904	10.7	23
192	Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. *Clinical Cancer Research*, **2012**, 18, 1870-8	12.9	23
191	Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. *Cancers*, **2019**, 11,	6.6	22
190	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?. *Neoplasia*, **2019**, 21, 93-105	6.4	22
189	Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. *Leukemia*, **2016**, 30, 2351-2363	10.7	21
188	A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. *Leukemia*, **2016**, 30, 1440-3	10.7	21
187	Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. *American Journal of Hematology*, **2013**, 88, 24-31	7.1	21
186	EGFR through STAT3 modulates N63 expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas. *Journal of Cellular Physiology*, **2013**, 228, 871-8	7	21
185	Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma. *British Journal of Haematology*, **2005**, 131, 214-8	4.5	21
184	The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA. *Nucleic Acids Research*, **2015**, 43, 5182-93	20.1	20
183	Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias. *Leukemia*, **2003**, 17, 125-32	10.7	20
182	Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. *Haematologica*, **2019**, 104, e72-e76	6.6	20
181	Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. *Haematologica*, **2021**, 106, 185-195	6.6	19
180	B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. *Hematological Oncology*, **2014**, 32, 22-30	1.3	19
179	Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?. *Leukemia*, **2012**, 26, 1703-7	10.7	19

178	Cyclin D1 protein expression is related to clinical progression in laryngeal squamous cell carcinomas. *Journal of Laryngology and Otology*, **1997**, 111, 622-6	1.8	19
177	Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. *Modern Pathology*, **2003**, 16, 886-92	9.8	19
176	Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening. *Oncotarget*, **2015**, 6, 34629-48	3.3	19
175	Utilizing next-generation sequencing in the management of multiple myeloma. *Expert Review of Molecular Diagnostics*, **2017**, 17, 653-663	3.8	18
174	Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. *Haematologica*, **2018**, 103, e245-e248	6.6	18
173	Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. *Expert Opinion on Biological Therapy*, **2013**, 13 Suppl 1, S55-68	5.4	18
172	Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. *International Journal of Molecular Sciences*, **2015**, 16, 17514-34	6.3	18
171	Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. *Genes Chromosomes and Cancer*, **2007**, 46, 1109-18	5	18
170	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2015**, 56, 3150-8	1.9	17
169	Long non-coding RNAs in B-cell malignancies: a comprehensive overview. *Oncotarget*, **2017**, 8, 60605-60623	5.3	17
168	Primary plasma cell leukemia in the era of new drugs: has something changed?. *Critical Reviews in Oncology/Hematology*, **2012**, 82, 141-9	7	17
167	PI3K/AKT signaling inhibits NOTCH1 lysosome-mediated degradation. *Genes Chromosomes and Cancer*, **2015**, 54, 516-526	5	17
166	Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL. *British Journal of Haematology*, **2010**, 149, 160-3	4.5	17
165	Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. *Hematological Oncology*, **2009**, 27, 23-30	1.3	17
164	Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. *Human Pathology*, **2003**, 34, 41-7	3.7	17
163	EHT, a New Member of the MTG8/ETO Gene Family, Maps on 20q11 Region and Is Deleted in Acute Myeloid Leukemias. *Blood*, **1998**, 92, 3481-3484	2.2	17
162	Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance. *Haematologica*, **2020**, 105, 1925-1936	6.6	16
161	Long Non-Coding RNAs in Multiple Myeloma. *Genes*, **2018**, 9,	4.2	16

160	Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: a comparative study. *Genes Chromosomes and Cancer*, **2011**, 50, 726-34	5	16
159	IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia. *British Journal of Haematology*, **2006**, 133, 50-8	4.5	16
158	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. *International Journal of Cancer*, **2004**, 112, 71-7	7.5	15
157	Mechanism of activation and biological role of the c-myc oncogene in B-cell lymphomagenesis. *Annals of the New York Academy of Sciences*, **1987**, 511, 207-18	6.5	15
156	Clonal evolution in therapy-related neoplasms. *Oncotarget*, **2017**, 8, 12031-12040	3.3	15
155	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. *Cancers*, **2020**, 12,	6.6	14
154	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. *Histopathology*, **2006**, 48, 529-35	7.3	14
153	Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. *JAMA Otolaryngology*, **2004**, 130, 303-6		14
152	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. *Cancers*, **2020**, 12,	6.6	14
151	Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. *Leukemia Research*, **2017**, 57, 65-71	2.7	13
150	Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?. *Leukemia and Lymphoma*, **2014**, 55, 1261-5	1.9	13
149	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. *American Journal of Hematology*, **2014**, 89, 743-50	7.1	13
148	Heterogeneity of Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. *Frontiers in Oncology*, **2020**, 10, 593383	5.3	13
147	Primary Plasma Cell Leukemia: Identity Card 2016. *Current Treatment Options in Oncology*, **2016**, 17, 19	5.4	13
146	Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells. *Cancer Letters*, **2017**, 410, 201-211	9.9	12
145	Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. *American Journal of Hematology*, **2018**, 93, E35-E37	7.1	12
144	Primary plasma cell leukemia 2.0: advances in biology and clinical management. *Expert Review of Hematology*, **2016**, 9, 1063-1073	2.8	12
143	External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. *Cancer*, **2013**, 119, 1177-85	6.4	12

142	p53 tumour suppressor gene and RAS oncogenes: molecular analysis in the chronic and leukaemic phases of essential thrombocythaemia. *British Journal of Haematology*, **1996**, 93, 670-3	4.5	12
141	Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. *PLoS ONE*, **2015**, 10, e0118801	3.7	12
140	Targeting Notch as a Therapeutic Approach for Human Malignancies. *Current Pharmaceutical Design* , **2017**, 23, 108-134	3.3	12
139	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 20	7	11
138	Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?. *International Journal of Hematology*, **2017**, 105, 104-108	2.3	11
137	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. *American Journal of Hematology*, **2013**, 88, 277-82	7.1	11
136	The clinical and biological features of a series of immunophenotypic variant of B-CLL. *European Journal of Haematology*, **2010**, 85, 120-9	3.8	11
135	Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. *International Journal of Hematology*, **2008**, 88, 374-380	2.3	11
134	Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines. *Haematologica*, **2005**, 90, 1541-8	6.6	11
133	LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?. *Non-coding RNA*, **2020**, 6,	7.1	10
132	Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. *Leukemia Research*, **2015**, 39, 840-5	2.7	10
131	Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2012**, 53, 424-9	1.9	10
130	Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). *Leukemia Research*, **2013**, 37, 809-15	2.7	10
129	Functional and multimarker analysis of T-cell chronic lymphocytic leukaemia. *Scandinavian Journal of Haematology*, **1985**, 34, 88-96		10
128	Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. *Toxicology*, **2011**, 283, 18-23	4.4	10
127	Analysis of tumor-specific immunoglobulin gene rearrangement in peripheral blood B-cells of multiple myeloma patients. *American Journal of Hematology*, **1991**, 37, 1-5	7.1	10
126	Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening. *PLoS ONE*, **2017**, 12, e0182640	3.7	10
125	In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma. *Genes* , **2016**, 7,	4.2	10

124	Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach. *Molecular Medicine*, **2020**, 26, 25	6.2	9
123	Pathogenicity of In Vivo Generated Intestinal Th17 Lymphocytes is IFNDependent. *Journal of Crohn's and Colitis*, **2018**, 12, 981-992	1.5	9
122	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. *American Journal of Hematology*, **2018**, 93, E216-E219	7.1	9
121	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. *Cellular Oncology (Dordrecht)*, **2017**, 40, 483-496	7.2	9
120	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. *Genes Chromosomes and Cancer*, **2014**, 53, 264-73	5	9
119	Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. *American Journal of Hematology*, **2011**, 86, E64-6	7.1	9
118	Trophoblast giant cells express NF-kappa B2 during early mouse development. *Genesis*, **1999**, 25, 23-30		9
117	Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture. *Oncotarget*, **2017**, 8, 14620-14635	3.3	9
116	Global methylation patterns in primary plasma cell leukemia. *Leukemia Research*, **2018**, 73, 95-102	2.7	9
115	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. *Leukemia*, **2018**, 32, 1869-1873	10.7	8
114	Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. *European Journal of Haematology*, **2009**, 83, 208-14	3.8	8
113	Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. *Biochemical Pharmacology*, **2009**, 78, 1139-47	6	8
112	The transcriptomic profile of CD138 cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged. *Haematologica*, **2019**, 104, e465-e469	6.6	7
111	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. *American Journal of Hematology*, **2019**, 94, 628-634	7.1	7
110	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. *British Journal of Haematology*, **2015**, 168, 455-9	4.5	7
109	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. *Science Translational Medicine*, **2018**, 10,	17.5	7
108	Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study. *American Journal of Hematology*, **2013**, 88, 539-44	7.1	7
107	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis. *Leukemia Research*, **2013**, 37, 943-7	2.7	7

106	Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. *Leukemia*, **2010**, 24, 1368-70	10.7	7
105	Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. *Journal of Pathology*, **2003**, 200, 596-601	9.4	7
104	Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology. *Non-coding RNA*, **2020**, 6,	7.1	7
103	Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. *Blood Advances*, **2020**, 4, 4312-4326	7.8	7
102	IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia. *Leukemia*, **2019**, 33, 1519-1522	10.7	7
101	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. *Expert Opinion on Investigational Drugs*, **2020**, 29, 869-880	5.9	6
100	Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy). *Blood Advances*, **2020**, 4, 2996-2999	7.8	6
99	Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line. *Genes Chromosomes and Cancer*, **2014**, 53, 154-67	5	6
98	The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. *Experimental Hematology*, **2011**, 39, 55-65	3.1	6
97	The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods. *Leukemia and Lymphoma*, **2008**, 49, 1907-15	1.9	6
96	Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma. *Hematological Oncology*, **2007**, 25, 6-10	1.3	6
95	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. *Blood*, **1999**, 93, 1330-1337	2.2	6
94	The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma. *Cancers*, **2021**, 13,	6.6	6
93	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. *European Journal of Haematology*, **2016**, 96, 36-45	3.8	6
92	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. *Haematologica*, **2020**, 105, 1613-1620	6.6	6
91	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. *Haematologica*, **2020**, 105, 2420-2431	6.6	5
90	Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. *European Journal of Haematology*, **2018**, 101, 703	3.8	5
89	Intraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia. *Molecular Medicine*, **2011**, 17, 834-9	6.2	5

88	Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation. *British Journal of Haematology*, **2004**, 126, 437-9	4.5	5
87	Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1. *BMC Genomics*, **2003**, 4, 9	4.5	5
86	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. *Blood Cancer Journal*, **2020**, 10, 92	7	5
85	Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. *HemaSphere*, **2020**, 4, e402	0.3	5
84	Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia. *British Journal of Haematology*, **2016**, 175, 983-985	4.5	5
83	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. *American Journal of Hematology*, **2021**, 96, E168-E171	7.1	5
82	Antitumor Effects of PRIMA-1 and PRIMA-1 (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. *Cells*, **2021**, 10,	7.9	5
81	Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. *Cancers*, **2020**, 12,	6.6	4
80	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. *Non-coding RNA*, **2020**, 6,	7.1	4
79	A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI). *Clinical Immunology*, **2016**, 172, 52-60	9	4
78	Long term assessment of intralipotherapy in Madelung's disease. *Indian Journal of Plastic Surgery*, **2014**, 47, 427-31	0.9	4
77	Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. *Leukemia Research*, **2011**, 35, 808-13	2.7	4
76	An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0. *Acta Haematologica*, **2012**, 127, 149-51	2.7	4
75	p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. *Blood*, **1993**, 81, 128-135	2.2	4
74	Critical analysis of transcriptional and post-transcriptional regulatory networks in multiple myeloma. *Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing*, **2010**, 397-408	1.3	4
73	Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients. *Scientific Reports*, **2020**, 10, 18427	4.9	4
72	Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities. *Cancers*, **2021**, 13,	6.6	4
71	Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing. *Blood Cancer Journal*, **2019**, 9, 21	7	4

70	Biological and molecular characterization of a rare case of cutaneous Richter syndrome. *Hematological Oncology*, **2017**, 35, 869-874	1.3	3
69	Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression. *Blood Cancer Journal*, **2017**, 6, e513	7	3
68	Genomic profiling of enzastaurin-treated B cell lymphoma RL cells. *Hematological Oncology*, **2011**, 29, 154-6	1.3	3
67	Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?. *Advances in Hematology*, **2009**, 2009, 287974	1.5	3
66	Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2008**, 49, 62-7	1.9	3
65	Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple myeloma cell line. *Leukemia*, **2001**, 15, 864-5	10.7	3
64	A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14). *Leukemia*, **2002**, 16, 1201-2	10.7	3
63	EHT, a New Member of the MTG8/ETO Gene Family, Maps on 20q11 Region and Is Deleted in Acute Myeloid Leukemias. *Blood*, **1998**, 92, 3481-3484	2.2	3
62	Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol. *European Journal of Haematology*, **2021**, 106, 831-835	3.8	3
61	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. *American Journal of Hematology*, **2021**, 96, E306-E310	7.1	3
60	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. *Blood*, **2021**, 138, 1705-1720	2.2	3
59	Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. *Drug Design, Development and Therapy*, **2021**, 15, 2969-2978	4.4	3
58	miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma. *Cancers*, **2021**, 13,	6.6	3
57	Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). *Hematological Oncology*, **2019**, 37, 505-507	1.3	2
56	Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients. *Hematological Oncology*, **2020**, 38, 406-408	1.3	2
55	COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death. *Cancer Letters*, **2020**, 476, 106-119	9.9	2
54	Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma. *Cancers*, **2020**, 12,	6.6	2
53	Next-generation sequencing in multiple myeloma: insights into the molecular heterogeneity of the disease. *International Journal of Hematologic Oncology*, **2014**, 3, 367-376	1	2

52	Should pre-transfusion screening RBC panels contain Wr(a+) cells?. *Transfusion Medicine*, **2010**, 20, 337-40	1.3	2
51	Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. *British Journal of Haematology*, **2010**, 150, 229-32	4.5	2
50	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. *Leukemia Research*, **2010**, 34, e217-8	2.7	2
49	Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent In Situ Hybridization. *Blood*, **1999**, 94, 724-732	2.2	2
48	Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective. *Cancers*, **2021**, 13,	6.6	2
47	DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. *Haematologica*, **2021**,	6.6	2
46	What Is New in the Treatment of Smoldering Multiple Myeloma?. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
45	Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma **1998**, 79, 263		2
44	Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity.. *Biomedicines*, **2022**, 10,	4.8	2
43	Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. *Pathology and Oncology Research*, **2017**, 23, 281-286	2.6	1
42	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. *Leukemia Research*, **2008**, 32, 1628-32	2.7	1
41	Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma. *Journal of Laryngology and Otology*, **2002**, 116, 610-2	1.8	1
40	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. *Blood*, **2018**, 132, 1834-1834	2.2	1
39	Tryptophan Deprivation Promotes an Adaptive Response and Contributes to Bioenergetics in Multiple Myeloma. *Blood*, **2018**, 132, 4511-4511	2.2	1
38	Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia. *Blood*, **2012**, 120, 729-729	2.2	1
37	Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study.. *Thrombosis Research*, **2022**, 210, 67-69	8.2	1
36	ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
35	Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNF IL-6 and IL-11 cytokines. *Haematologica*, **2021**, 106, 2598-2612	6.6	1

34	Repetitive DNA Hypomethylation in Multiple Myeloma. *Blood*, **2008**, 112, 2703-2703	2.2	1
33	Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells. *Cancers*, **2020**, 12,	6.6	1
32	Halting the FGF/FGFR axis leads to antitumor activity in Waldenstr¶m macroglobulinemia by silencing MYD88. *Blood*, **2021**, 137, 2495-2508	2.2	1
31	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. *European Journal of Haematology*, **2021**, 106, 493-499	3.8	1
30	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. *Frontiers in Oncology*, **2021**, 11, 684621	5.3	1
29	Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 6479-6490	12.9	1
28	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. *Cancers*, **2021**, 14,	6.6	1
27	Response of AIHA to high dose intravenous immunoglobulins in a patient with ovarian teratoma. *European Journal of Clinical Investigation*, **2009**, 39, 531-2	4.6	0
26	In Vitro Silencing of lncRNAs Using LNA GapmeRs. *Methods in Molecular Biology*, **2021**, 2348, 157-166	1.4	0
25	CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network. *Methods in Molecular Biology*, **2021**, 2348, 189-204	1.4	0
24	Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine. *Clinical Hematology International*,1	1.8	0
23	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). *Haematologica*, **2020**, 105, 2671-2674	6.6	
22	Arrangements and rearrangements of the human T-cell receptor gamma gene. *Annals of the New York Academy of Sciences*, **1987**, 511, 232-45	6.5	
21	Meeting report on recent advances on T-lymphocytes in normal and leukemia patients. *International Journal of Cell Cloning*, **1985**, 3, 330-42		
20	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study NVeritasN*Blood*, **2020**, 136, 47-49	2.2	
19	RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma. *Blood*, **2020**, 136, 20-21	2.2	
18	Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma. *Blood*, **2020** , 136, 3-4	2.2	
17	Impact of Genetic Predisposition on Glyco-Metabolic Side Effects of TKIs in CML. *Blood*, **2020**, 136, 5-5	2.2	

List of Publications

16	Sphingosine Kinase 1 as a Potential Target To Inhibit Proliferation of Myeloid Leukemia Cells.. *Blood*, **2007**, 110, 4196-4196	2.2
15	Molecular and Transcriptional Characterization of the Novel 17p11.2-p12 Chromosome Amplification in Multiple Myeloma.. *Blood*, **2007**, 110, 2486-2486	2.2
14	Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles.. *Blood*, **2007**, 110, 2482-2482	2.2
13	Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstr□¶m Macroglobulinemia. *Blood*, **2018**, 132, 1585-1585	2.2
12	Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines. *Blood*, **2015**, 126, 3019-3019	2.2
11	A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. *Blood*, **2015**, 126, 2930-2930	2.2
10	The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4. *Blood*, **2015**, 126, 5315-5315	2.2
9	Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia.. *Blood*, **2008**, 112, 1062-1062	2.2
8	HOXB7 Overexpression in Mesenchymal Cells Stimulates the Production of Pro-Angiogenic Molecules: Potential Role in Multiple Myeloma Associated Angiogenesis. *Blood*, **2008**, 112, 2743-2743	2.2
7	Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Patients in Early Stage Disease,. *Blood*, **2011**, 118, 3890-3890	2.2
6	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell Receptors. *Blood*, **2011**, 118, 2847-2847	2.2
5	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. *Blood*, **2012**, 120, 1780-1780	2.2
4	The Genomics of Multiple Myeloma and Its Relevance in the Molecular Classification and Risk Stratification of the Disease **2013**, 543-570	
3	MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL). *Blood*, **2013**, 122, 4172-4172	2.2
2	Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. *Cell Reports*, **2021**, 34, 108845	10.6
1	Bioinformatics Pipeline to Analyze lncRNA Arrays. *Methods in Molecular Biology*, **2021**, 2348, 45-53	1.4